189 related articles for article (PubMed ID: 20046923)
1. Positron Emission Tomography Imaging of Hypoxia.
Lapi SE; Voller TF; Welch MJ
PET Clin; 2009 Jan; 4(1):39-47. PubMed ID: 20046923
[TBL] [Abstract][Full Text] [Related]
2. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
Dietz DW; Dehdashti F; Grigsby PW; Malyapa RS; Myerson RJ; Picus J; Ritter J; Lewis JS; Welch MJ; Siegel BA
Dis Colon Rectum; 2008 Nov; 51(11):1641-8. PubMed ID: 18682881
[TBL] [Abstract][Full Text] [Related]
3. Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.
Bonnitcha PD; Bayly SR; Theobald MB; Betts HM; Lewis JS; Dilworth JR
J Inorg Biochem; 2010 Feb; 104(2):126-35. PubMed ID: 19932509
[TBL] [Abstract][Full Text] [Related]
4. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
Chao KS; Bosch WR; Mutic S; Lewis JS; Dehdashti F; Mintun MA; Dempsey JF; Perez CA; Purdy JA; Welch MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1171-82. PubMed ID: 11240261
[TBL] [Abstract][Full Text] [Related]
5. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.
Dehdashti F; Grigsby PW; Mintun MA; Lewis JS; Siegel BA; Welch MJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1233-8. PubMed ID: 12654432
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia imaging agents labeled with positron emitters.
Hoigebazar L; Jeong JM
Recent Results Cancer Res; 2013; 194():285-99. PubMed ID: 22918765
[TBL] [Abstract][Full Text] [Related]
7. Imaging of hypoxia in mouse atherosclerotic plaques with (64)Cu-ATSM.
Nie X; Randolph GJ; Elvington A; Bandara N; Zheleznyak A; Gropler RJ; Woodard PK; Lapi SE
Nucl Med Biol; 2016 Sep; 43(9):534-542. PubMed ID: 27372286
[TBL] [Abstract][Full Text] [Related]
8. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
9. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
[TBL] [Abstract][Full Text] [Related]
10. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
Furukawa T; Yuan Q; Jin ZH; Aung W; Yoshii Y; Hasegawa S; Endo H; Inoue M; Zhang MR; Fujibayashi Y; Saga T
Oncol Rep; 2015 Sep; 34(3):1379-87. PubMed ID: 26134305
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia imaging and theranostic potential of [
Liu T; Karlsen M; Karlberg AM; Redalen KR
EJNMMI Res; 2020 Apr; 10(1):33. PubMed ID: 32274601
[TBL] [Abstract][Full Text] [Related]
12. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography.
Matsumoto K; Szajek L; Krishna MC; Cook JA; Seidel J; Grimes K; Carson J; Sowers AL; English S; Green MV; Bacharach SL; Eckelman WC; Mitchell JB
Int J Oncol; 2007 Apr; 30(4):873-81. PubMed ID: 17332926
[TBL] [Abstract][Full Text] [Related]
13. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
Dehdashti F; Grigsby PW; Lewis JS; Laforest R; Siegel BA; Welch MJ
J Nucl Med; 2008 Feb; 49(2):201-5. PubMed ID: 18199612
[TBL] [Abstract][Full Text] [Related]
14. Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging.
Colombié M; Gouard S; Frindel M; Vidal A; Chérel M; Kraeber-Bodéré F; Rousseau C; Bourgeois M
Front Med (Lausanne); 2015; 2():58. PubMed ID: 26380261
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
[TBL] [Abstract][Full Text] [Related]
16. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM.
Holland JP; Lewis JS; Dehdashti F
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):193-200. PubMed ID: 19293767
[TBL] [Abstract][Full Text] [Related]
17. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.
Dehdashti F; Mintun MA; Lewis JS; Bradley J; Govindan R; Laforest R; Welch MJ; Siegel BA
Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):844-50. PubMed ID: 12692685
[TBL] [Abstract][Full Text] [Related]
18. PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update.
Baskin A; Buchegger F; Seimbille Y; Ratib O; Garibotto V
Curr Vasc Pharmacol; 2015; 13(2):209-17. PubMed ID: 24188484
[TBL] [Abstract][Full Text] [Related]
19. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia.
Vāvere AL; Lewis JS
Dalton Trans; 2007 Nov; (43):4893-902. PubMed ID: 17992274
[TBL] [Abstract][Full Text] [Related]
20. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
